Replies to post #193918 on Cytodyn Inc (CYDY)

[crazyjogger925]

very fine article here re leronlimab in tnbc

https://www.cancernetwork.com/view/leronlimab-provides-a-significant-survival-benefit-in-metastatic-triple-negative-breast-cancer

[HyGro]

Interesting Dr. Kelly did comparisons on overall survival but he was very deceptive.

Most cancer trials are for relapsed/refractory tumors. Whereas LL was screened for only naive patients -- the easiest to treat. The R/R have already failed on at least two standard of care treatments and are the hard cases.

But Dr. Kelly did his comparison of LL's naive patients to other mTNBC treatments trials for R/R. It is clearly deceptive as he did not even reference that difference that is very significant to the trial outcomes.

More and more Cytodyn misrepresentation. And all while the SEC is already investigating for doing just that!!! But anything to pump the stock.

[HyGro]

Considering Dr. Kelly used a very misleading comparison of the results of LL in naïve mTNBC patients to two other drugs results in relapsed and refractory mTNBC that have failed at least two or more other treatments. It is deceptive and misleading naïve retail investors who don't know any better. You see that the mTNBC and NASH results pressers got very small positive impact so the company seems to have lost it's credibility.